Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Conditions
Interventions
CDX-3379 and cetuximab
Locations
10
United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
Yale Cancer Center
New Haven, Connecticut, United States
Emory University Winship Cancer Institute
Atlanta, Georgia, United States
Rush University Medical center
Chicago, Illinois, United States
Washington University School of Medicine
St Louis, Missouri, United States
University of Cincinnati
Cincinnati, Ohio, United States
Start Date
March 27, 2018
Primary Completion Date
September 16, 2020
Completion Date
December 16, 2020
Last Updated
April 3, 2023
NCT05039801
NCT07371234
NCT04533750
NCT07405086
NCT06959108
NCT04733495
Lead Sponsor
Celldex Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions